Syngene International
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Syngene International is currently navigating a challenging transition as it shifts from commoditized research services to higher-value specialized modalities. Management has indicated a near-term revenue de-growth due to reduced demand from its key biologics client, Zoetis, and a lack of immediate revenue-generating alternatives. This aligns with Vista's forecast of stable revenue growth but highlights potential margin pressures as the company executes its strategic pivot. Despite these challenges, long-term growth prospects remain promising, supported by investments in AI-enabled drug discovery and high-growth clinical capabilities. The industry context, characterized by a stable growth trajectory for Indian CDMOs, further reinforces Syngene's strategic direction. However, the mixed demand recovery and regulatory pressures present watchpoints for the next 12-24 months. Key opportunities include the expansion of India's biopharma market and the company's focus on integrated CRDMO partnerships, while headwinds include execution risks at new facilities and slower client decision-making. Overall, Vista's outlook reflects cautious optimism, with a hold recommendation and a target price that suggests limited upside in the near term
Why We Like This Stock
- Long-term growth prospects supported by investments in AI-enabled drug discovery and high-growth clinical capabilities
- India's strengthening position as a preferred scientific services hub due to global supply chain diversification
- Strategic focus on high-growth areas like complex peptides and GLP-1 therapies enhances future revenue potential
Things To Watch Out For
- Near-term revenue de-growth driven by reduced demand from key clients and execution risks at new facilities
- Mixed demand recovery and slower client decision-making may hinder short-term growth
- Regulatory pressures, including the US Biosecure law, could impact operational efficiency and client retention
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 3,489 | 3,642 | 3,739 | 3,343 | 3,453 |
| Profit Before Tax (Cr.) | 635 | 631 | 488 | 229 | 327 |
| PBT Margin | 18.2% | 17.3% | 1305.2% | 6.9% | 9.5% |
| Net Profit (Cr.) | 504 | 498 | 383 | 181 | 258 |
| Earnings Per Share | 12.5 | 12.3 | 9.5 | 4.5 | 6.4 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Goldman Sachs | ▲ Buy | 450 | 31-Jul-2026 |
| Jeffries | ▼ Underperform | 410 | 04-May-2026 |
| Kotak Securities | ▲ Buy | 680 | 25-Jun-2026 |
| Macguire | ▲ Outperform | 735 | 30-Jul-2026 |
| Moneycontrol | ▲ Overweight | nan | 31-Jul-2026 |
Company Overview
Show Company Profile
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.